Product Description
Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve symptoms of arthritis (osteoarthritis and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure arthritis and will help you only as long as you continue to take it. (Sourced from: https://www.mayoclinic.org/drugs-supplements/flurbiprofen-oral-route/precautions/drg-20069793?p=1)
Mechanisms of Action: COX1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Transdermal, Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Jiudian Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Japan
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pain, Postoperative
Phase 1: Agammaglobulinemia|Communicable Diseases|Healthy Volunteers|Inflammation|Myalgia|Osteoarthritis|Respiratory Tract Infections|Shoulder Pain|Tennis Elbow|Tenosynovitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618000249257p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Agammaglobulinemia |
2018-03-18 |
|||
jRCT2031240583 |
jRCT2031240583 | P1 |
Not yet recruiting |
Inflammation |
2025-05-31 |
|||
NCT05955885 |
NCT05955885 | P1 |
Completed |
Respiratory Tract Infections|Communicable Diseases |
2024-07-01 |
23% |
2024-12-07 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
CTR20223348 |
CTR20223348 | P1 |
Completed |
Myalgia|Tennis Elbow|Tenosynovitis|Shoulder Pain|Osteoarthritis |
2023-03-02 |
2025-04-29 |
||
jRCT2031230393 |
jRCT2031230393 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-03-31 |
|||
CTR20171260 |
CTR20171260 | P2 |
Recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20171653 |
CTR20171653 | P3 |
Recruiting |
Pain, Postoperative |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20210443 |
CTR20210443 | P3 |
Recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/20/2025 |
News Article |
Phillips 66 and Kinder Morgan, Inc. Announce Binding Open Season for Western Gateway Pipeline |
|
08/18/2025 |
News Article |
Sino Biopharm (1177.HK) Announces 2025 Interim Results |
|
07/16/2025 |
News Article |
Kinder Morgan Reports Second Quarter 2025 Financial Results |
|
10/16/2024 |
News Article |
Kinder Morgan Reports Third Quarter 2024 Financial Results |